Katholieke Universiteit Leuven

Katholieke Universiteit Leuven, Ku Leuven R&d

Remynd

Remynd Nv

K. U. Leuven R&d Remynd

Katholieke Universiteit Levun

Patrick Chaltin

Arnaud Marchand

Amuri Kilonda

Sara Allasia

Gerard Griffioen

Tom Van Dooren

Zeger Debyser

Frauke Christ

Arnout Voet

Marc De Maeyer

Damien Marchand

Veronica Rojas De La Parra

Katrien Princen

Dorothée Bardiot

Arnaud Didier Marie Marchand

Thomas Voets

Joris Vriens

Johan Gerard Griffioen

Tom Francois L Van Dooren

André Welbers

Jean-Christophe Vanherck

Verónica Rojas De La Parra

Melanie Reich

Wim Smets

Gunter Carlens

Karin Thevissen

Bruno Cammue

Sara Alassia

Philippe Arzel

Arnaud Didier Marchand

Tom Francois Van Dooren

Tom François L Van Dooren

The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.

Heterocycle derivatives for treating TRPM3 mediated disorders

The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R, R, R, Rand R, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases.

Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders

The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R, R, R, Rand R, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases. 

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic &#x3b1;-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases

The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.

Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic &#x3b1;-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R, R, R, R, R, E, n, Y, Y, Y, Y, Y, B, R, and m are as defined in the claims. 

Compounds for the treatment of neurodegenerative diseases

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic &#x3b1;-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R, R, R, R, E, n, Y, Y, Y, Y, Y, L, B, R, and m are as defined in the claims. 

The present invention relates to compounds of formula (A), as further defined herein, having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. The invention further relates to the use of such compounds, optionally combined with one or more other drugs having antiviral activity, for the treatment of animals suffering from viral infections, in particular HIV infection. 

Antiviral compounds

The present invention relates to a series of novel compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutical amount of such compounds, optionally combined with one or more other drugs having antiviral activity.

Viral replication inhibitors

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic &#x3b1;-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. 

Growing community of inventors

Jodoigne, Belgium

Patrick Chaltin